Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
High-amylose maize resistant starch type 2 is a dietary fiber ingredient derived from conventionally bred varieties of high-amylose corn. It consists primarily of non-digestible (resistant) starch that resists enzymatic digestion in the small intestine and reaches the colon largely intact. Classified as a "type 2" resistant starch (RS2), it is not chemically modified and is naturally present in certain foods. Its primary mechanisms include improving glycemic management by moderating postprandial blood glucose response, supporting digestive health through fermentation by colonic bacteria to produce short-chain fatty acids, and contributing to energy management. The FDA has authorized a qualified health claim stating that consumption of this ingredient may reduce the risk of type 2 diabetes based on limited scientific evidence[1][2][4]. It is used as a functional food ingredient to replace flour or increase fiber content in various products such as breads, cookies, cereals, and pastas without affecting taste or texture[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on high-amylose maize resistant starch type 2.